Atrial of arbidol hydrochloride in adults with COVID-19  

作　　者：Jingya Zhao Jinnong Zhang Yang Jin Zhouping Tang Ke Hu Hui Sun Mengmeng Shi Qingyuan Yang Peiyu Gu Hongrong Guo Qi Li Haiying Zhang Chenghong Li Ming Yang Nian Xiong Xuan Dong Juanjuan Xu Fan Lin Tao Wang Chao Yang Bo Huang Jingyi Zhang hi Chen Qiong He Min Zhou Jieming Qu 

机构地区：[1]Department of Pulmonary and Critical Care Medicine,Rujin Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200025,China [2]institute of Respiratory Diseases,School of Medicine,Shanghai Jiao Tong University,Shanghai 200025,China [3]Department of Emergency,Union Medical College Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430058,China [4]Department of Respiratory and Critical Care Medicine,Union Medical Collge Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430058,China [5]Department of Neurology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430030,China [6]Department of Respiratory and Critical Care Medicine,Renmin Hospital,Wuhan University,Wuhan,Hubei 430060,China [7]Department of Endocrinology,Union Medical Cllege Affiliated to Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei 430058,China [8]Department of Respiratory Medicine,Wuhan Bauhinia Hospital,Wuhan,Hubei 430062,China [9]Department of Respiratory Medicine,Guanggu Hospital District,The Third Hospital of Wuhan,Wuhan,Hubei 430074,China [10]Department of Respiratory and Crtical Care Medicin,Puren Hosptal,Wuhan University of Science and Technology,Wuhan,Hubei 430081,China [11]Department of Respiratory Medicine,The Third People's Hospital of Hubei Province,Wuhan,Hubei 430030,China [12]Department of Respiatory Medicine,The Sixth General Hospital of Hubei Province,Wuhan,Hubei 430015,China [13]Tuberculosis Department of Chengdu Public Health Clinical Medical Center,Chengdu,Sichuan 610066,China [14]Department of Neurology,Wuhan Red Cross Hospital,Wuhan,Hubei 430015,China [15]Department of Tuberculosis,Jinyintan Hospia,Wuhan,Hubei 430048,China [16]Department of Cardiology,The Third People's Hospital of Hubei Province,Wuhan,Hubei 430030,China.

出　　处：《Chinese Medical Journal》2022年第13期1531-1538,共8页中华医学杂志（英文版）

基　　金：Shanghai Top-Priority Clinical Key Disciplines Construction Project(No.2017ZZ02014);Shanghai Key Laboratory of Emergency Prevention,Diagnosis and Treatment of Respiratory Infectious Diseases(No.20dz2261100);Cultivation Project of Shanghai Major Infectious Disease Research Base(No.20dz2210500)。

摘　　要：Background: To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods: This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results: A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled;66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64]vs. 42.4% [14/33];difference of conversion rate 27.9%;95% confidence interval [CI], 7.7%-48.1%;P=0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 daysvs. 12.0 days;hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060,P=0.006), symptom of fever (median 3.0 daysvs. 12.0 days;HR: 18.990, 95% CI: 5.350-67.410,P<0.001), as well as hospitalization (median 12.5 daysvs. 20.0 days;P<0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 daysvs. 14.5 days;P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions: SOC plus arbidol tablets significant

关 键 词：ARBIDOL Coronavirus disease 2019(COVID-19) Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) 

分 类 号：R563.1[医药卫生—呼吸系统]